25122-57-0
中文名稱(chēng)
丁酸氯倍他松
英文名稱(chēng)
Clobetasone butyrate
CAS
25122-57-0
EINECS 編號(hào)
246-635-9
分子式
C26H32ClFO5
MDL 編號(hào)
MFCD00133196
分子量
478.98
MOL 文件
25122-57-0.mol
更新日期
2026/05/28 11:26:34
25122-57-0 結(jié)構(gòu)式
基本信息
中文別名
丁酸倍氯他松丁酸氯倍他松
氯倍他松丁酸酯
英文別名
(16-beta)-)11,20-trione,21-chloro-9-fluoro-17-hydroxy-16-beta-methyl-pregna-4-diene-3
21-chloro-9-fluoro-17-hydroxy-16-beta-methylpregna-1,4-diene,3,11,20-trione
eumovate
molivate
pregna-1,4-diene-3,11,20-trione,21-chloro-9-fluoro-16-methyl-17-(1-oxobutoxy
sn203
21-chloro-9-fluoro-17-hydroxy-16beta-methylpregna-1,4-diene-3,11,20-trione 17-butyrate
ClobetasolPropionate-Bp/Ep/Usp
Butyric acid, ester with 21-chloro-9-fluoro-17-hydroxy-16β-methylpregna-1,4-diene-3,11,20-trione (8CI)
CCl 5537
Emovate
GR 2/1214
Kindavate
Pregna-1,4-diene-3,11,20-trione, 21-chloro-9-fluoro-16-methyl-17-(1-oxobutoxy)-, (16β)-
Pregna-1,4-diene-3,11,20-trione, 21-chloro-9-fluoro-17-hydroxy-16β-methyl-, butyrate (8CI)
21-Chloro-9-fluoro-17-hydroxy-16b-methylpregna-1,4-diene-3,11,20-trione 17-butyrate
Clobetasone butyrate
Clobetasone-17-butyrate
CLOBETASOLE BUTYRATE
所屬類(lèi)別
分析化學(xué)：藥典標(biāo)準(zhǔn)品和雜質(zhì)標(biāo)準(zhǔn)品物理化學(xué)性質(zhì)
熔點(diǎn)90-100°
沸點(diǎn)573.3±50.0 °C(Predicted)
密度1.1736 (estimate)
儲(chǔ)存條件Refrigerator, Under Inert Atmosphere
溶解度Practically insoluble in water, freely soluble in acetone and in methylene chloride, slightly soluble in ethanol (96 per cent).
形態(tài)neat
顏色白色至灰白色
穩(wěn)定性穩(wěn)定的。易燃。與強(qiáng)氧化劑不相容。
InChIKeyFBRAWBYQGRLCEK-JGSYYNBSNA-N
SMILES[C@]1(C(=O)CCl)(OC(=O)CCC)[C@@H](C)C[C@@]2([H])[C@]3([H])CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)C(=O)C[C@]12C |&1:0,11,14,16,26,28,33,r|
CAS 數(shù)據(jù)庫(kù)25122-57-0(CAS DataBase Reference)
常見(jiàn)問(wèn)題列表
用途
丁酸氯倍他松是一種外用糖皮質(zhì)激素藥，具有較強(qiáng)的毛細(xì)血管收縮作用，臨床上主要用于治療皮膚病。
生物活性
Clobetasone butyrate是一種新型的皮質(zhì)類(lèi)固醇，經(jīng)常用于治療濕疹、牛皮癬、皮膚炎和某些眼科疾病。靶點(diǎn)
IC50: glucocorticoid
體內(nèi)研究
Clobetasone butyrate (application on the skin; 0.05%; 7 weeks) induces epidermal thinning in skin, Clobetasone butyrate 7 weeks causes much less epidermal thinning in the pig than flurandrenolone (0.05%) or fluocinolone acetonide (0.025%), both of which causes severe atrophy.
| Animal Model: | Large white domestic pig |
| Dosage: | 0.5% application on the skin |
| Administration: | 7 weeks |
| Result: | Caused moderate to slight atrophy. |